300765 CSPC Innovation Pharmaceutical
- 26.79
- -0.56-2.05%
CSPC Innovation Pharmaceutical News
Express News | CSPC Innovation Pharmaceutical: SYS6043 antibody-drug conjugate has received clinical trial approval.
Express News | Cspc innovation pharmaceutical: The application for issuing shares to purchase assets and raise supporting funds has been accepted.
CSPC Innovation Pharmaceutical Get US FDA Fast Track Qualification for Cervical Cancer Drug
Express News | cspc innovation pharmaceutical: cspc pharma giant stone biopharmaceutical co., ltd. authorized drug obtains fast track designation from the usa FDA.
Express News | cspc innovation pharmaceutical: The market application for Ustinue monoclonal antibody injection has been accepted.
cspc innovation pharmaceutical (300765.SZ): Giant Stone Biological's therapeutic vaccine SYS6026 has been approved to conduct clinical trials.
Gelonghui November 12th 丨 CSPC Innovation Pharmaceutical (300765.SZ) announced that its holding subsidiary CSPC Pharma Horizepharma Co., Ltd. (hereinafter referred to as “Horizepharma”) recently received the Drug Clinical Trial Approval Notice for the Therapeutic Vaccine SYS6026 for the treatment of related precancerous lesions caused by human papillomavirus (HPV) issued by the National Medical Products Administration, and will soon conduct clinical trials. SYS6026 is the company's first therapeutic vaccine developed based on its mRNA platform, delivered by messenger RNA (mRNA) molecules bound to lipid nanoparticles (LNP).
Express News | cspc innovation pharmaceutical: SYS6026 injection solution approved for clinical trials.
Express News | This week, nearly 30 listed companies disclosed information on share buybacks, shareholding, and related re-loans. CNGR Advanced Material plans to repurchase shares with a special loan not exceeding 0.7 billion yuan.
CSPC Innovation Pharmaceutical (300765.SZ): The controlling shareholder plans to increase shareholding of 0.1 billion yuan to -0.12 billion yuan in the company's shares.
Graind 7th November, CSPC Innovation Pharmaceutical (300765.SZ) announced that the company recently received a notification from its controlling shareholder, CSPC Pharma Group Enbipu Pharmaceutical Co., Ltd. (referred to as "Enbipu Pharmaceutical"), stating that Enbipu Pharmaceutical plans to increase its shareholding in the company within 6 months starting from the date of this announcement (including this day), with the amount of shareholding not less than 100 million yuan and not more than 120 million yuan.
From cspc innovation pharmaceutical to Stone Medicine Innovation, what has changed is not just the R&D expenses.
From active pharmaceutical ingredients to innovative drugs, from focusing on current profits to focusing on product pipeline and cash flow.
New Novus: third quarter report 2024
CSPC Innovation Pharmaceutical's quarterly net profit hit a new low, with Hengrui Bio's research and development expenses exceeding four billion in the first three quarters. | Interpretations of Financial Reports
①Affected by the low price of caffeine and the increase in R&D investment of Giantstone Biopharmaceutical, CSPC Innovation Pharmaceutical handed in a three-quarter report with declining performance. ②Q3 of this year has also become the worst quarter in terms of the company's profitability so far. ③After planning for more than 9 months, CSPC Innovation Pharmaceutical's acquisition of Stone Pharmaceuticals has finally made new progress last week.
CSPC Innovation Pharmaceutical's Q3 Profit Plunges 98%
CSPC Pharma (01093): CSPC Innovation (300765.SZ) recorded a net profit attributable to equity holders of approximately 0.139 billion yuan in the first three quarters, a decrease of 63.5% year-on-year.
CSPC Pharma (01093) Announced the performance of CSPC Innovation (300765.SZ) in the third quarter of 2024, operating...
Express News | cspc innovation pharmaceutical: net income in the third quarter decreased by 98.03% year-on-year.
Shiyao Group 'hand-shaped' cspc innovation pharmaceutical Hebei tycoon again pushes for 7.6 billion acquisition
How is a market cap of 40 billion achieved? Recently, Cai Jun from Investor Web reported that cspc innovation pharmaceutical (300765.SZ, referred to as the 'company') publicly announced a 7.6 billion yuan acquisition proposal. As a subsidiary of cspc pharma that spun off to the gem, the company has been planning this acquisition for a long time. In fact, in recent years, the controlling family of the group has significantly increased the company valuation through internal assets shuffling, integration, and injection. In the cold environment of the pharmaceutical industry, they have demonstrated their capital skills. However, the smooth capital operation may not significantly improve performance. Whether cspc innovation pharmaceutical's valuation can remain strong remains to be tested by time. Only time will tell.
HK stock unusual movement | cspc pharma (01093) is currently up more than 7%, cspc innovation pharmaceutical plans to acquire cspc pharma bak, cspc pharma reaches cooperation with astrazeneca.
CSPC Pharma (01093) is now up over 7%, as of the time of writing, up 6.91%, trading at 6.5 Hong Kong dollars, with a turnover of 0.818 billion Hong Kong dollars.
cspc innovation pharmaceutical (300765.SZ): Enrabizumab injection has been successfully launched for sales.
On October 17, Gelonhui reported that CSPC Innovation Pharmaceutical (300765.SZ) held a performance briefing on October 15, 2024, regarding whether the Enralongsu monoclonal antibody injection has started generating revenue. The company stated that the Enralongsu monoclonal antibody injection has been launched for sales.
cspc innovation pharmaceutical (300765.SZ): Currently, the company's caffeine product prices are relatively stable
Gelonghui October 17th | cspc innovation pharmaceutical (300765.SZ) held a performance briefing on October 15, 2024, addressing the question "How is the expected price change of caffeine in the second half of the year?" The company stated that currently the prices of the company's caffeine products are relatively stable.
CSPC Innovation Pharmaceutical (300765): Restructuring into the current pharmaceutical main line, acquiring Shi Yao Bai Ke, and continuously integrating high-quality assets.
Investment highlights: Event: On October 15, the company announced the acquisition of 100% equity of Shiyaobaik, through issuing shares and paying cash, while raising supporting funds to acquire Shiyaobaik, another integration of high-quality innovative drugs following Jushibiotech.
No Data
